

Finch Announces Resignation of Domenic Ferrante from the Board of Directors and Appointment of Stephen McCall as an Independent Director

BOSTON, September 25, 2025 -- Finch Therapeutics Group, Inc. (the “Company”) (OTC: FNCH) today announced that Domenic Ferrante has resigned from the Board of Directors (the “Board”) of the Company, effective as of September 19, 2025. The decision of Mr. Ferrante to resign as a member of the Board was not the result of any disagreement between him and the Company on any matters relating to the Company’s operations, policies or practices. Stephen McCall has been appointed as an independent member of the Board effective immediately. Mr. McCall is a restructuring expert with extensive experience serving as an independent director for publicly-traded and private companies in various industries facing significant capital challenges.

For investor inquiries, please contact:

mblischak@finchtherapeutics.com

For media inquiries, please contact:

info@finchtherapeutics.com